Samjin Pharmaceuticals Co., Ltd. (KRX: 005500)

Market Cap	239.91B
Revenue (ttm)	274.03B
Net Income (ttm)	21.89B
Shares Out	12.77M
EPS (ttm)	1,727.82
PE Ratio	10.87
Forward PE	n/a
Dividend	800.00 (4.21%)
Ex-Dividend Date	n/a

Volume	11,446
Open	18,910
Previous Close	18,990
Day's Range	18,730 - 19,050
52-Week Range	17,110 - 23,450
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 19, 2024

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 586
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005500

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.